4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults

BACKGROUND: Immunocompromised (IC) populations are at increased risk of developing herpes zoster (HZ) due to disease- and/or therapy-induced immunosuppression. The adjuvanted recombinant zoster vaccine (RZV) has demonstrated 68.2% efficacy in preventing HZ in autologous hematopoietic stem cell trans...

Full description

Saved in:
Bibliographic Details
Published in:Open Forum Infect Dis
Main Authors: Dagnew, Alemnew F, Vink, Peter, Drame, Mamadou, Willer, David, Salaun, Bruno, Schuind, Anne
Format: Artigo
Language:Inglês
Published: Oxford University Press 2020
Subjects:
Oral Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7776102/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa417.003
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items